🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#News: We’ve announced positive topline results from the Phase 3 inMIND trial in patients with relapsed or refractory follicular lymphoma (FL).

Good news for the patients #lymsm

📢We look forward to welcoming you at the 7th Annual Meeting of the IACH including the COMydAL, COLYM, and MPNCo&D tracks on Sept 19-21, in Paris and online. The meeting platform is open! HOW TO ACCESS? See the links to the Lecture Halls⬇️ iachlive.cme-congresses.com Mohamad Mohty

Big success for ELI's 10th Workshop on "Lymphoma of immune privilege sites" held last week in Stresa!

Long awaited IELSG37 Trial Results: Patients with mediastinal large B-cell lymphoma who achieve Deauville scores of 1-3 on PET after immunochemotherapy have excellent outcomes and do not require consolidative radiation therapy. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Excited to share 2 year follow-up of SWOG Cancer Research Network S1826: Nivolumab+AVD vs. BV-AVD in Advanced-Stage Classic Hodgkin Lymphoma NEJM Wilmot Cancer Institute nejm.org/doi/full/10.10…

Salles: 5y POLARIX FU - sustained PFS benefit for Pola-R-CHP (65% v 59%) - 23% reduced subseq Rx - Reduced 2nd malig (?due to less subseq Rx) - OS no difference but MAY see a difference emerging - 7y FU planned Reassuring data - will be using 1L for IPI 2-5. #ASH24 #lymsm

Interesting to see the different trends in lymphoma related mortality…maybe this is anticipating some OS differences in the future

It was a true honour to be part of this practice changing study #inmind for RR FL. Main messages in addition to better efficacy…fixed duration w/o excess events after tx stop, no added toxicity, excellent TTNT…works in high risk pts, my best choice for 2L FL. #lymsm #ash24

Pod24 is not forever in FL…learn why and read Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study - HemaSphere - #lymsm #flsm onlinelibrary.wiley.com/doi/full/10.10…

📢Save the Date! 🩸The 8th Annual Meeting of the IACH including the COMydAL, COLYM and MPNCo&D tracks October 9-11, 2025 🗼Paris and online ✨Registration is open! iach.cme-congresses.com/registration/ We look forward to an engaging and inspiring meeting that will shape the future of

🩸The 8th Annual Meeting of the IACH including the COMydAL, COLYM and MPNCo&D tracks 🩺👨‍⚕️Travel grant offer for young participants click below to register: bit.ly/43jKGWg Sign up for your spot TODAY this offer is limited only until July 31st, 2025 Meeting Information

Insightful annual gathering of the IELSG in Stresa. At-a-glance: MZL, PMBL, CNSL, NKTCL, lots of ongoing interventional trials and PET/translational studies With colleagues from: FIL_ETS Lysa Lymphoma SAKK GELTAMO UK NCRI, Poland, China, Brazil… Cc ICML Conference C. Thieblemont

2025 edition of the Cantera just started in Lyon…20 rising stars in the lymphoma field coached by a great coach Gilles Salles European Hematology Association @filonlus #lymsm

TMTV is back as a strong prognostic factor in follicular lymphomas…#lymsm #flsm @filonlus American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/aj…

Sharing ideas to acheive international colaboración in linfomas. The aim is to develop relevant information to try to improve the prognosis of our patients. Thank you @massimofederico ⁦Stefano Luminari, MD⁩ ⁦Andrés Ferreri⁩ @mariagomesdasouza

This is an interesting case of a patient with concomitant MALT lymphoma and an autoimmune disease who was treated with BsAb...both diseases completely responded to therapy...haematologica.org/haematologica/…

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment ashpublications.org/blood/article-…

CONGRESS | #EHA2025 | PRESENTATION Stefano Luminari, MD, UNIMORE, presented long-term efficacy and safety findings from the phase II ELM-2 trial (NCT03888105) evaluating odronextamab in patients with relapsed/refractory follicular #lymphoma (N = 128). At a median follow-up of

Good rides with great friends with the growing “ciclismo Lugano Linfomi” team #ICML2025 International Conference on Malignant Lymphoma